230 related articles for article (PubMed ID: 11524770)
1. [Interferons in the treatment of hematological diseases].
Jantunen E; Nousiainen T
Duodecim; 1998; 114(12):1240-7. PubMed ID: 11524770
[No Abstract] [Full Text] [Related]
2. [Interferons. Treatment of malignant hemopathies with interferons].
Guilhot F; Sadoun A; Delwail V
Ann Med Interne (Paris); 1993; 144(8):548-56. PubMed ID: 7513980
[TBL] [Abstract][Full Text] [Related]
3. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1997; 17():390-407. PubMed ID: 9551222
[No Abstract] [Full Text] [Related]
4. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1999; 18():268-92. PubMed ID: 10800488
[No Abstract] [Full Text] [Related]
5. Clinical and biological activity of the interferons in hematologic malignancies.
Gutterman JU
Prog Clin Biol Res; 1989; 288():337-48. PubMed ID: 2470111
[No Abstract] [Full Text] [Related]
6. [Interferon therapy in hematologic neoplasms].
Schwarzinger I; Bettelheim P; Lechner K
Wien Klin Wochenschr; 1988 Aug; 100(15):497-504. PubMed ID: 2459854
[TBL] [Abstract][Full Text] [Related]
7. [Current status and future perspective of new drugs for hematological malignancies in Japan].
Ogura M
Rinsho Ketsueki; 2007 Oct; 48(10):1442-52. PubMed ID: 17933133
[No Abstract] [Full Text] [Related]
8. [Treatment of hematologic diseases with alpha interferon].
Castaigne S
Bull Cancer; 1988; 75(9):859-62. PubMed ID: 3207895
[TBL] [Abstract][Full Text] [Related]
9. Biotherapy with interferon in hematologic malignancies.
Roth MS; Foon KA
Oncol Nurs Forum; 1987; 14(6 Suppl):16-22. PubMed ID: 2447569
[No Abstract] [Full Text] [Related]
10. [Hematological aspects of acro-syndromes].
Schmidt PM
Rev Med Suisse Romande; 1992 May; 112(5):413-6. PubMed ID: 1604102
[No Abstract] [Full Text] [Related]
11. Therapy with interferons in blood diseases.
Polli E; Cortelezzi A
Acta Haematol; 1987; 78 Suppl 1():64-9. PubMed ID: 2449025
[TBL] [Abstract][Full Text] [Related]
12. Biotherapy with interferon--1988.
Figlin RA
Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
[TBL] [Abstract][Full Text] [Related]
13. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
14. [The standard treatments for patients with hematological malignancies in Japan].
Ishizawa K
Gan To Kagaku Ryoho; 2007 May; 34(5):709-12. PubMed ID: 17496442
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
Orciuolo E; Fazzi R; Galimberti S; Testi C; Azzara' A; Carulli G; Petrini M
Leuk Res; 2006 Mar; 30(3):349-53. PubMed ID: 16182365
[TBL] [Abstract][Full Text] [Related]
16. Biotherapy in clinical practice.
Figlin RA
Semin Hematol; 1989 Jul; 26(3 Suppl 3):15-24. PubMed ID: 2477904
[TBL] [Abstract][Full Text] [Related]
17. Interferon therapy of hematologic malignancies.
Foon KA
Cancer Treat Res; 1998; 94():1-21. PubMed ID: 9587679
[No Abstract] [Full Text] [Related]
18. Interferons for the treatment of hematological malignancies.
Urabe A
Oncology; 1994; 51(2):137-41. PubMed ID: 7515169
[TBL] [Abstract][Full Text] [Related]
19. [Neutrophil function in hematologic disorders].
Matzner Y
Harefuah; 1991 Dec; 121(11):449-52. PubMed ID: 1786895
[No Abstract] [Full Text] [Related]
20. [Interferon-alpha in therapy of malignant hemoblastoses].
Schuler M; Aulitzky WE; Schneller F; Peschel C; Huber C
Internist (Berl); 1995 Dec; 36(12):1133-8. PubMed ID: 8567218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
